A Prospective, Multi-Center Study to Evaluate the Efficacy and Safety of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia Patients
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to evaluate the efficacy and safety of venetoclax combined with azacitidine regimen for newly diagnosed T-ALL patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 15
Healthy Volunteers: f
View:
• Patients aged ≥ 15.
• Patients diagnosed with T-ALL according to 2016 WHO criteria for precursor lymphoid neoplasms.
• ECOG performance status score less than 3.
• Patients without serious heart, lung, liver, or kidney dysfunction.
• Ability to understand and voluntarily provide informed consent.
Locations
Other Locations
China
The First Affliated Hospital of Soochow University
RECRUITING
Suzhou
Time Frame
Start Date: 2022-04-01
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 28
Treatments
Experimental: Venetclax combined with Azacitidine
T-cell acute lymphoblastic leukemia patients reveive venetoclax combined with azacitidine regimen treatment.
Related Therapeutic Areas
Sponsors
Leads: The First Affiliated Hospital of Soochow University
Collaborators: Northern Jiangsu People's Hospital, Affiliated Hospital of Nantong University, The First Affiliated Hospital of Bengbu Medical University, Jining Medical University, Suzhou Hospital of Traditional Chinese Medicine, The Second People's Hospital of Huai'an